Introduction {#sec1-1}
============

Fermented milk has been proven to improve and maintain human health. It relates to the biological activities found in fermented milk, such as antioxidant, immunomodulatory, anti-inflammatory, antibacterial, anticancer, and antihypertensive activities \[[@ref1]-[@ref4]\]. Antihypertensive activity of fermented milk is one of the interesting areas due to the increases of hypertension cases and side effects caused by the use of synthetic drugs such as captopril, lisinopril, and enalapril \[[@ref5]\]. Angiotensin-I-converting enzyme (ACE, EC 33.4.15.1, CD143) plays a key role in the blood pressure regulation system. ACE converts inactive decapeptide Angiotensin I to the potent vasoconstrictor, i.e., the octapeptide Angiotensin II and also inactivates bradykinin, a vasodilator \[[@ref6],[@ref7]\]. ACE is one of the effective targets to reduce blood pressure. ACE-inhibitory (ACE-I) peptides can be isolated from fermented milk and are a safe, natural source to be used in the treatment of hypertension. Milk protein is a precursor of bioactive peptides \[[@ref8]-[@ref10]\], but most of the peptides in milk are inactive that requiring hydrolysis to release them. Fermentation of milk involving lactic acid bacteria (LAB) such as in yogurt, cheese, and other fermented milk is a method known to hydrolyze proteins and release bioactive peptides from the primary protein structure \[[@ref11],[@ref12]\]. The proteolytic system makes LAB as a prospective producer of bioactive antihypertensive peptides in fermented food products \[[@ref13],[@ref14]\]. Proteolytic activity of LAB varies between species and even strains. Therefore, it is necessary to find a LAB with high proteolytic activity to produce bioactive antihypertensive peptide. The LAB which has been reported by several researchers as being able to produce bioactive antihypertensive peptides in fermented milk among others are *Lactobacillus helveticus* \[[@ref13],[@ref15]\], *Lactobacillus plantarum*, *Lactobacillus pentosus*, *Pediococcus acidilactici*, *Pediococcus pentosaceus*, *Lactobacillus delbrueckii* ssp. *bulgaricus*, and *Lactococcus ­lactis* \[[@ref16],[@ref17]\]. *L. helveticus* has been widely used in dairy products to generate ACE-I peptides \[[@ref18]\]. Calpis, which is a soft drink manufactured in Japan, is produced from milk fermented by a mixture of *L. helveticus* CP790 and *Saccharomyces cerevisiae* \[[@ref19]\]. Two bioactive peptides with ACE-I activity have been identified in calpis, i.e., Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP). VPP and IPP peptides have the same structure as captopril and enalapril \[[@ref20]\] commonly used in hypertension therapy \[[@ref21]\].

Screening of LAB capable of producing bioactive peptides as ACE-I and characterization of the resulted peptides are essential to obtain isolates that can be used as starter cultures to produce fermented milk containing antihypertensive peptides. The availability of indigenous LAB with the ability to produce specific peptides as a starter culture will also contribute to the diversification of fermented milk products as a functional food.

This study aimed to explore the capacity of ten indigenous LAB that previously has been isolated from tempe, kefir, and breast milk to generate ACE-I peptides and to characterize the ACE-I peptides generated.

Materials and Methods {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

No animals were used in the present study, so there was no requirement of ethical approval.

LAB {#sec2-2}
---

The ten LAB were *P. pentosaceus* 1 W2SR04, *L. plantarum* 1 W22408, *Lactobacillus rhamnosus* R2, *Lactobacillus* R7F, *L. delbrueckii* BD7, *L. lactis* ssp. *lactis* BD17, *Lactobacillus* *fermentum* R6, S206, and *Lactobacillus kefiri* YK4 and JK17 that previously have been isolated from tempe, kefir, and breast milk were obtained from Food Microbiology Laboratory of the Southeast Asian Food and Agricultural Science and Technology (SEAFAST) Center, IPB University, Bogor, Indonesia.

Fermentation of milk {#sec2-3}
--------------------

The LAB isolates were refreshed by growing them in De Man, Rogosa, and Sharpe broth (Oxoid, USA) and incubated at 37°C for 24 h. To prepare inoculum for milk fermentation, the isolates were inoculated into 11% skim milk and incubated for 24 h at 37°C. The starter culture (2%) was inoculated into pasteurized (95°C for 10 min) reconstituted skim milk (11% NZWP Ltd., NZ) and then incubated at 37°C to reach pH 4.6 (pH 700 Eutech). When the pH has been reached, the LAB count and titratable acidity were analyzed. The fermentation process was then stopped by heating at 75°C for 1 min. The fermented milk was then centrifuged (Hettich, Zentrifugen, Mikro 22R) at 6000× *g* 10 min at 4°C. For the analysis of soluble protein, peptide, and ACE-I activity, the supernatant was collected. The titratable acidity was determined by the titration, while the LAB was enumerated on De Man, Rogosa, and Sharpe Agar (Oxoid, USA).

Determination of peptide content {#sec2-4}
--------------------------------

The o-phthaldialdehyde (OPA) method was used to measure peptide content \[[@ref22]\]. A total of 50 µL samples were mixed with 2 mL of OPA reagents (consisting of 25 mL of 100 mM of sodium tetraborate, 2.5 mL of 20% (w/w) of sodium dodecyl sulfate, and 1.1 mL of OPA solution, mixed with 21.4 mL of dH~2~O). The OPA solution was prepared by dissolving 40 mg of OPA (Sigma, USA) in 1 mL of methanol+100 mL of ß-mercaptoethanol (Sigma, USA). The sample and OPA reagent were quickly mixed with and then incubated for 2 min, then the sample absorbance was measured at 340 nm (UV-VIS-1240, Shimadzu, Kyoto, JPN). The peptide content was quantified using the tryptone casein (Merck, USA) standard curve.

Determination of soluble protein content {#sec2-5}
----------------------------------------

Protein content was determined using the Bradford method \[[@ref23]\]. A total of 10 µL samples were mixed with 250 µL Bradford reagent and then incubated for 5 min. The absorbance of the sample was measured at 595 nm (Biorad, iMark, Microplate Reader, JPN). The protein content of the sample was calculated using a standard curve of bovine serum albumin (Sigma, USA).

Determination of ACE-I activity {#sec2-6}
-------------------------------

The determination of ACE-I activity was performed *in vitro* based on the method of Chusman and Cheung \[[@ref24]\]. Hippuryl-L-Histidyl-L-Leucine (HHL, Sigma, USA) was used as the enzyme-substrate. A 50 µL of the substrate (50 mM HHL in 0.1 M sodium borate buffer containing 0.3 M NaCl at pH 8.3) was added into 50 µL sample and incubated at 37°C for 5 min. To initiate the reaction, 50 µL of 0.1 U/mL ACE (Sigma, USA) solution was added, and the mixture was incubated at 37°C for 5 min. The reaction was stopped by adding 250 µL 1 M HCl 1 M. The resulted in hippuric acid (HA) was extracted with 1.5 mL ethyl acetate and centrifuged at 2000× *g* for 5 min. An aliquot (0.8 mL) of the ethyl acetate layer was transferred to a clean tube and evaporated at 85°C for 60 min. Distilled water (4 mL) was then added to dissolve the HA in the tube, and the amount of HA formed was measured by measuring optical density at 228 nm (UV-2800, Hitachi, JPN) The extent of inhibition was calculated as 100% (\[B-A\]/B) where A is the optical density in the presence of ACE and ACE-I component, B is the optical density without ACE-I component.

IC~50~ value {#sec2-7}
------------

The value of IC~50~ was calculated based on the equation obtained from the curve of ACE inhibition as a function of different concentrations of peptide. The value of IC~50~ is defined as the amount of peptide required to inhibit 50% of ACE activity.

Characterization of peptides from fermented milk {#sec2-8}
------------------------------------------------

### Partial purification {#sec3-1}

The supernatant of fermented milk that has the highest ACE-I activity was pipetted into ultrafiltration centrifuge tubes molecular weight (MW) cutoff of 3 kDa (Merck, Amicon Ultra-4 mL, Centrifugal Filters, IRL). We collected two fractions (MW \<3 kDa and MW \>3 kDa) and assayed their ACE-I activity.

### Identification of peptides by mass spectrometry (MS) {#sec3-2}

The characterization of peptide (MWs and amino acid sequences) was carried out in Advanced Research Laboratory, IPB University (Bogor Agricultural University) based on the method of Daliri *et al*. \[[@ref25]\] using Nano Liquid Chromatography (LC) Ultimate 3000 series system Tandem Q Exactive Plus Orbitrap high-resolution MS (Thermo Scientific, GER). Fractions \<3 kDa (5 µL) of the samples were injected into the LC-nano MS system. The samples were trapped on a trap column (Thermo Scientific, 164649, 30 µm×5 mm) and washed for 6 min with gradient with 98% Solvent A (water/acetonitrile \[98:2, v/v\], 0.1% formic acid) and 2% Solvent B (Water/acetonitrile \[2:98, v/v\], 0.1% formic acid) at a flow rate of 5 µL/min. The peptides were separated on a capillary column (PepMap RSLC-C18, 75-µm×150 mm, 3.5 µm particle size, 100 pore size, part number ES 800, Thermo Scientific) at a flow rate of 300 nL/min with gradient at 2-35% Solvent B over 30 min, then from 35% to 90% over 10 min, followed by 90% Solvent B for 5 min, and finally 5% Solvent B for 15 min. Electrospray was performed at an ion spray voltage of 3500 eV. The range of m/z values was 200-2000. The peptides were analyzed using Proteomic Discoverer 2.2 software.

Statistical analysis {#sec2-9}
--------------------

All analyses were carried out in triplicate and expressed as mean±standard deviation. The data obtained were analyzed by Analysis of Variance. The differences between means were assessed using the Duncan test and were considered significant when p≤0.05. Statistical analysis was performed using SPSS version 16 software (IBM Corp., NY, USA).

Results {#sec1-3}
=======

Growth of LAB in milk {#sec2-10}
---------------------

[Table-1](#T1){ref-type="table"} shows the growth of LAB, titratable acidity, and fermentation time required by 10 LAB to reach pH 4.5. Changes in pH due to the accumulation of lactic acid as a result of lactose metabolism during fermentation ranged from 0.77±0.06 to 0.91±0.06%. The fermentation time required to reach pH 4.6 by 10 LAB was 24-48 h. The lactic acid counts ranged from 9.11±0.22 to 9.62±0.28 log CFU/mL. The soluble protein content in the sample ranged from 0.215±0.01 to 0.395±0.00 mg/mL ([Table-1](#T1){ref-type="table"}).

###### 

Fermentation time, titratable acidity, viable count of LAB, and soluble protein content in fermented milk after pH 4.6 were reached.

  Starter culture                           Fermentation time (h)   Titratable acidity (%)   Viable LAB (log CFU/mL)   Soluble protein content (mg/mL)
  ----------------------------------------- ----------------------- ------------------------ ------------------------- ---------------------------------
  *Lactobacillus rhamnosus* R2              32                      0.77±0.06                9.46±0.36                 0.215±0.01
  *Lactobacillus kefiri* JK17               32                      0.84±0.05                9.62±0.40                 0.395±0.00
  *Lactobacillus delbrueckii* BD7           48                      0.83±0.04                9.41±0.25                 0.383±0.01
  *Lactobacillus fermentum* S206            48                      0.87±0.05                9.33±0.37                 0.277±0.01
  *Lactobacillus kefiri* YK4                32                      0.91±0.06                9.62±0.28                 0.343±0.00
  *Lactobacillus* R7F                       40                      0.84±0.02                9.11±0.22                 0.386±0.02
  *Lactobacillus fermentum* R6              24                      0.80±0.06                9.49±0.26                 0.384±0.01
  *Lactobacillus plantarum* 1W22408         32                      0.79±0.04                9.21±0.41                 0.277±0.01
  *Lactococcus lactis* ssp. *lactis* BD17   40                      0.82±0.08                9.25±0.42                 0.361±0.01

LAB=Lactic acid bacteria

ACE-I activity {#sec2-11}
--------------

The percentages of ACE-I activity, peptide content, and inhibitory efficiency ratio (IER) values in milk fermented by 10 LAB cultures are shown in [Table-2](#T2){ref-type="table"}. ACE-I activity ranged from 22.78±2.55% to 57.36±5.40% in fermented milk. ACE-I activity above 50% was found in milk fermented by *L. delbrueckii* BD7, *L. lactis* ssp. *lactis* BD17, and *L. kefiri* YK4 and JK17. The highest percentage of ACE-I was obtained in milk fermented by *L. kefiri* YK4 and *L. kefiri* JK17, but it was not significantly different (\>0.05) with milk fermented by *L. delbrueckii* BD7 and *L. lactis* ssp. *lactis* BD17. As a positive control, captopril was used which generated ACE-I activity of 87.5±1.05%.

###### 

ACE-inhibitory, peptide content, and IER in milk fermented by ten LAB cultures after reaching pH 4.6 incubated at 37°C.

  Starter culture                           \% inhibition of ACE   Peptide content (mg/mL)   IER (% per mg/mL)
  ----------------------------------------- ---------------------- ------------------------- -------------------
  *Lactobacillus rhamnosus* R2              22.78±2.55^e^          4.012±0.20^a^             5.68±0.62^e^
  *Lactobacillus kefiri* JK17               56.53±1.53^a^          3.976±0.17^a^             14.23±0.53^a^
  *Lactobacillus delbrueckii* BD7           50.97±2.46^ab^         3.727±0.27^ab^            13.79±1.60^ab^
  *Lactobacillus fermentum* S206            40.83±3.55^cd^         3.676±0.21^abc^           11.12±0.84^c^
  *Lactobacillus kefiri* YK4                57.36±5.40^a^          3.540±0.07^abcd^          16.24±1.85^a^
  *Lactobacillus* R7F                       27.78±2.89^e^          3.322±0.21^bcd^           8.44±1.32^d^
  *Lactobacillus fermentum* R6              44.86±1.87^bc^         3.266±0.22^bcd^           13.81±1.13^ab^
  *Lactobacillus plantarum* 1W22408         46.94±3.42^bc^         3.219±0.29^de^            14.81±0.70^a^
  *Lactococcus lactis* ssp. *lactis* BD17   52.22±4.86^ab^         3.211±0.26^de^            16.33±1.72^a^
  *Pediococcus pentosaceus* 1 W2SR04        35.14±3.27^d^          3.116±0.08^e^             11.27±0.99^c^
  Captopril                                 87.5±1.05                                        

ACE=Angiotensin-I-converting enzyme, IER=Inhibitory efficiency ratio

Different superscripts in the same column indicates significant (p\<0.05) between samples

IC~50~ value {#sec2-12}
------------

The IC~50~ value was measured in fermented milk with the highest activity of ACE-I (fermented milk of *L. kefiri* JK17 and YK4). Captopril was also measured as a control ([Table-3](#T3){ref-type="table"}). IC~50~ values reflect the concentration of peptide required to inhibit 50% ACE.

###### 

IC~50~ value of Captopril and milk fermented by *Lactobacillus kefiri* YK4 and *Lactobacillus kefiri* JK17.

  IC~50~ value (mg/mL)                                       
  ---------------------------- ----------------------------- ---------------
  *Lactobacillus kefiri* YK4   *Lactobacillus kefiri* JK17   Captopril
  0.261±3.94^a^                0.308±8.16^b^                 0.008±0.23^c^

Different superscripts in the same row indicates significant (p \< 0.05) between samples

Partial purification {#sec2-13}
--------------------

Results of filtration using a membrane with MW cutoff \<3 kDa yielded two fractions, i.e., \>3 kDa and 3 kDa with ACE-I activity as shown in [Table-4](#T4){ref-type="table"}. The whole supernatant of *L. kefiri* YK4 achieved the highest ACE-I activity (57.36±5.40%) but it was not significantly different (\>0.05) from the \<3 kDa fraction (55.45±1.97%). Meanwhile, the ACE-activity of the whole supernatant from milk fermented by *L. kefiri* JK17 (56.53±1.53%) was significantly higher than both fractions of \>3 kDa (24.03±1.64%) and \<3 kDa (52.28±4.09%).

###### 

ACE-I activity of supernatant, fractions of \>3 kDa and \<3 kDa in milk fermented by *Lactobacillus kefiri* YK4 and *Lactobacillus kefiri* JK17.

  Starter culture                ACE-I activity (%)                   
  ------------------------------ -------------------- --------------- ---------------
  *Lactobacillus kefir* YK4      57.36±5.40^a^        31.89±2.08^b^   55.45±1.97^a^
  *Lactobacillus kefir* i JK17   56.53±1.53^a^        24.03±1.64^b^   52.28±4.09^c^

ACE-I=Angiotensin-I-converting enzyme inhibitor

Different superscripts in the same row indicates significant (p \< 0.05) between samples

Identification of ACE-I peptides {#sec2-14}
--------------------------------

Peptide profile in fermented milk (\<3 kDa) by *L. kefiri* YK4 and *L. kefiri* JK17 is presented in [Table-5](#T5){ref-type="table"}. Identification of peptides in the fraction \<3 kDa showed that the majority of peptides had m/z values range of 317-1093 with MWs of 634-2079 Dalton, and the number of residues was 6-20 amino acids. The peptides produced from both samples were derived from the hydrolysis of the casein parent protein (αS1-casein, αS2-casein, β-casein, and κ-casein), ά- lactalbumin, β-lactoglobulin, and serum amyloid A.

###### 

Fermented milk peptide profile (\<3 kDa) of *Lactobacillus kefiri* YK4 and *Lactobacillus kefiri* JK17.

  Parent protein    Peptide total   Range of precursor m/z   Range of precursor MW   Amino acid residue                   Dominant peptide        LAB
  ----------------- --------------- ------------------------ ----------------------- ------------------------------------ ----------------------- ------
  αS1-casein        92              374-971                  747-1941                6-18                                 FSDIPNPIGSE             YK 4
  76                438-1040        876-2079                 7-19                    FSDIPNPIGSENSEKTTMP, FVAPFPEVFGKEK   JK 17                   
  αS2-casein        42              325-882                  810-1763                6-15                                 QGPIVLNPWDQVKR          YK 4
  33                424-680         848-2040                 7-17                    LYQGPIVLNPWDQVKRN                    JK 17                   
  β-casein          774             327-1093                 979-2185                6-18                                 MPFPKYPVEPF             YK 4
  38                317-1022        634-2044                 6-19                    MPFPKYPVEP                           JK 17                   
  κ-casein          362             300-954                  841-2038                6-18                                 ARHPHPHLSF              YK 4
  19                324-889         924-1777                 7-18                    FMAIPPKKNQD, VRSPAQILQ               JK 17                   
  ά- lactalbumin    21              400-750                  808-1499                7-13                                 KVGINYWLAH, FHTSGYDTQ   YK 4
  3                 563             1126                     10                      FHTSGYDTQA                           JK 17                   
  β-lactoglobulin   17              322-727                  775-1453                7-13                                 KALPMHIR                YK 4
  5                 382-622         802-1243                 7-11                                                         JK 17                   
  serum amyloid A   21              242-727                  998-1753                8-15                                 EWGRSGKDPNHFRPA         YK 4

A=Alanine (Ala), C=Cysteine (Cys), D=Aspartic acid (Asp), E=Glutamic acid (Glu), F=Phenylalanine (Phe), G=Glycine (Gly), H=Histidine (His), I=Isoleucine (Ile), K=Lysine (Lys), L=Leucine (Leu), M=Methionine (Met), N=Asparagine (Asn), P=Proline (Pro), Q=Glutamine (Gln), R=Arginine (Arg), S=Serine (Ser), T=Threonine (Thr), V=Valine (Val), W=Tryptophan (Trp), Y=Tyrosine (Tyr)

A total of 1329 peptides were found in the fermented milk of *L. kefiri* YK4 starter culture (the whole data are not presented). As much as, 95.6% of resulted peptides were originated from casein with the proportion of 58.24% β-casein, 27.24% κ-casein, 6.92% αS1-casein, and 3.16% αS2-casein. Other peptides were 1.58% α-lactalbumin, 1.28% β-lactoglobulin, and 21.58% serum amyloid A. The dominant peptides derived from β-casein were identified as ARHPHPHLSF and MPFPKYPVEPF ([Table-5](#T5){ref-type="table"}). In fermented milk supernatant of *L. kefiri* JK17, 174 peptides were identified (the whole data are not shown). The peptides found were 95% derived from casein with the proportion of 43% αS1-casein, 21.8% β-casein, 19% αS2-casein, and 10.9% κ-casein. Other peptides were 1.7% ά-lactalbumin and 2.9% β-lactoglobulin. The dominant peptides found were identified as FSDIPNPIGSENSEKTTMP, FVA PFPEVFGKEK, LYQGPIVLNPWDQVKRN, and MPFPKYPVEP ([Table-5](#T5){ref-type="table"}).

The distribution of peptides is presented in [Figure-1](#F1){ref-type="fig"}. Based on the type of peptide, 480 different peptides were found in samples with starter culture *L. kefiri* YK4 and 110 peptides in samples with starter culture *L. kefiri* JK17. A total of 27 similar peptides were found in both samples.

![Distribution of identified peptides in fermented milk of *Lactobacillus kefiri* YK4 and JK17 in total peptides and for all parent protein, i.e., αS1-, αS2, β- and κ-casein, ά-lactalbumin, β-lactoglobulin, and amyloid A.](Vetworld-13-345-g001){#F1}

The identification of peptides with ACE-I activity was performed by searching the peptides that have been reported in the literature. [Table-6](#T6){ref-type="table"} shows the peptides that were reported to have ACE-I activity. The ACE-I peptides presented in [Table-6](#T6){ref-type="table"} are only homologous peptides (sequence similarity: 100%) to the peptides that have been reported to have ACE-I activity \[[@ref26]-[@ref43]\].

###### 

ACE-I peptides produced in fermented milk using *Lactobacillus kefiri* YK4 and JK17 as starter culture compared to ACE-I peptides as reported in the literature.

  Parent protein   Sequence peptide     m/z \[Da\]   MH+ \[Da\]   Charge   ACE-I peptides based on literature   
  ---------------- -------------------- ------------ ------------ -------- ------------------------------------ --------------
  K-casein         ARHPHPHLSFM          443.89       1329.66      3        ARHPHPHLSFM                          \[[@ref26]\]
  β-casein         DELQDKIHPF           621.31       1241.61      2        DELQDKIHPF                           \[[@ref27]\]
  β-casein         DKIHPF               378.71       756.41       2        DKIHPF                               \[[@ref28]\]
  β-casein         DKIHPFAQ             478.25       955.50       2        DKIHPFAQ                             \[[@ref29]\]
  β-casein         ELQDKIHPF            563.80       1126.59      2        ELQDKIHPF                            \[[@ref28]\]
  β-casein         EMPFPKYPVEPF         740.86       1480.72      2        EMPFPKYPVEPF                         \[[@ref30]\]
  αS1-casein       FVAPFPEV             453.24       905.48       2        FVAPFPEV                             \[[@ref31]\]
                                                                           FVAPFPEV                             \[[@ref32]\]
  αS1-casein       FVAPFPEVFG           555.29       1109.57      2        FVAPFPEVFG                           \[[@ref30]\]
                                                                           FVAPFPEVFG                           \[[@ref32]\]
  αS1-casein       FVAPFPEVFGK          619.33       1237.66      2        FVAPFPEVFGK                          \[[@ref33]\]
  αS1-casein       FVAPFPEVFGKE         683.85       1366.70      2        FVAPFPEVFGKE                         \[[@ref31]\]
  β-casein         GPVRGPFPI            470.27       939.54       2        GPVRGPFPI                            \[[@ref34]\]
  αS1-casein       IGSENSEKTTMP         647.30       1293.60      2        IGSENSEKTTMP                         \[[@ref35]\]
  β-casein         LGPVRGPFP            470.27       939.54       2        LGPVRGPFP                            \[[@ref36]\]
  β- casein        LVYPFPGPIHNSLPQ      839.95       1678.89      2        LVYPFPGPIHNSLPQ                      \[[@ref30]\]
  β- casein        LVYPFPGPIHNSLPQN     896.97       1792.93      2        LVYPFPGPIHNSLPQN                     \[[@ref3]\]
  β-casein         LYQEPVLGPVRGPFPIIV   997.58       1994.14      2        LYQEPVLGPVRGPFPIIV                   \[[@ref31]\]
  β-casein         MPFPKYPVEP           602.80       1204.60      2        MPFPKYPVEP                           \[[@ref35]\]
  β-casein         MPFPKYPVEPF          676.34       1351.67      2        MPFPKYPVEPF                          \[[@ref37]\]
  β-casein         QEPVLGPVRGPFP        696.88       1392.76      2        QEPVLGPVRGPFP                        \[[@ref36]\]
                                                                           QEPVLGPVRGPFP                        \[[@ref38]\]
  β-casein         QEPVLGPVRGPFPIIV     859.50       1718.00      2        QEPVLGPVRGPFPIIV                     \[[@ref39]\]
                                                                           QEPVLGPVRGPFPIIV                     \[[@ref40]\]
  β-casein         RDMPIQAF             489.25       977.49       2        RDMPIQAF                             \[[@ref41]\]
  αS1-casein       RPKHPIKH             338.21       1012.61      3        RPKHPIKH                             \[[@ref29]\]
  β-casein         SQSKVLPVPQ           541.81       1082.62      2        SQSKVLPVPQ                           \[[@ref35]\]
  αS1-casein       VAPFPEVFGK           545.80       1090.59      2        VAPFPEVFGK                           \[[@ref38]\]
  αS1-casein       VAPFPEVFGKE          610.32       1219.63      2        VAPFPEVFGKE                          \[[@ref32]\]
  β-casein         VLGPVRGPFP           519.81       1038.61      2        VLGPVRGPFP                           \[[@ref42]\]
  β-casein         YPFPGPIPN            501.26       1001.51      2        YPFPGPIPN                            \[[@ref43]\]
  β-casein         YQEPVLGPVR           579.32       1157.63      2        YQEPVLGPVR                           \[[@ref43]\]
  β-casein         YQEPVLGPVRGPFPI      556.98       1668.91      3        YQEPVLGPVRGPFPI                      \[[@ref33]\]
  β-casein         YQEPVLGPVRGPFPIIV    941.03       1881.06      2        YQEPVLGPVRGPFPIIV                    \[[@ref31]\]
                                                                           YQEPVLGPVRGPFPIIV                    \[[@ref33]\]

A=Alanine (Ala), C=Cysteine (Cys), D=Aspartic acid (Asp), E=Glutamic acid (Glu), F=Phenylalanine (Phe), G=Glycine (Gly), H=Histidine (His), I=Isoleucine (Ile), K=Lysine (Lys), L=Leucine (Leu), M=Methionine (Met), N=Asparagine (Asn), P=Proline (Pro), Q=Glutamine (Gln), R=Arginine (Arg), S=Serine (Ser), T=Threonine (Thr), V=Valine (Val), W=Tryptophan (Trp), Y=Tyrosine (Tyr)

Discussion {#sec1-4}
==========

During milk fermentation by LAB, the bacteria ferment lactose into organic acid, mainly lactic acid, and bring the pH down. The time to reach pH 4.6 varied between LAB showing the difference in the rate of growth. Short fermentation time (24 h) was observed in milk fermented by *P. pentosaceus* 1 W2SR04 and *L. fermentum* R6, while the longest fermentation time (48 hours) occurred in milk fermented by *L. delbrueckii* BD7 and *L. fermentum* S206. A previous study by Chen *et al*. \[[@ref13]\] report that the time to reach a pH of 4.6 by 37 *Lactobacillus* varied from 7 to 42.4 h. Meanwhile, *L. delbrueckii* QS306 required incubation time of 48 h to reach a pH of less than 4.7 \[[@ref44]\].

All LAB isolates grew well during fermentation, with a population of more than 9 log CFU/mL ([Table-1](#T1){ref-type="table"}). A similar result of a viable count of LAB in fermented milk was reported by Elkhtab *et al*. \[[@ref45]\] that of eight LAB dominated by *Lactobacillus* in fermented milk reached the population of 9.5 log CFU/mL after 72 h incubation. Similarly, in the fermented milk of *L. delbrueckii* ssp. *bulgaricus* 1466, the population reached \>8 log CFU/mL when the fermented milk reaches a pH 4.5 \[[@ref46]\].

The LAB also hydrolyzes protein in milk into peptides and amino acids to support their growth. Protein hydrolysis by LAB produces bioactive peptides acting as ACE-Is. The activity of ACE-I produced in fermented milk varies between LAB fermenting the milk \[[@ref21],[@ref42]\] and is strain-specific \[[@ref47]\]. *L. delbrueckii* and *L. lactis* isolates that produce high ACE-I activity in this study were similar to the previous report by Wu *et al*. \[[@ref48]\] that *L. delbrueckii* strain QS306 could produce 75.58±1.69% of ACE-I activity in fermented milk and *L. lactis* ADP strains Q1, Q2, and Q5 could produce 90-98% of ACE-I activity after 48 h fermentation \[[@ref49]\]. Meanwhile, the ACE-I activity in milk fermented by *L. kefiri* that isolated from kefir has not been reported.

ACE-I activity produced in fermented milk is associated with LAB's proteolytic activity. LAB's proteolytic activity generates several peptides. The peptides produced in this study ranged from 3.116±0.08 to 4.012±0.20 mg/mL. The highest peptide content was produced in milk fermented by *L. rhamnosus* R2 and *L. kefiri* JK17, but it was not significantly different from milk fermented by *L. delbrueckii* BD7, *L. kefiri* YK4, and *L. fermentum* S206. A high proteolytic activity has been reported in *Lactobacillus* species. The report has led to the widespread use of *Lactobacillus* species for the production of antihypertensive peptides (ACE-Is) \[[@ref41],[@ref50]\] in the fermented milk industry, such as sour milk and yogurt.

The peptide content, however, does not always correlate with the activity of ACE-I. The results obtained in this research show a poor correlation between peptide content and ACE-I activity ([Table-2](#T2){ref-type="table"}). Similar results were also obtained by Chen *et al*. \[[@ref13]\], where the percentage of ACE-I showed a poor correlation with the amount of free amino acid in fermented milk of *L. helveticus*. Similar results were also observed in milk fermented by *Leuconostoc mesenteroides* 356 \[[@ref3],[@ref51]\]. Each LAB will produce different pieces of the peptide with its specific proteolytic system. Bioactive peptides with the potential of ACE-I are specific peptides. The peptide type determines the activity of ACE-Is. However, high proteolytic activity is needed to produce several bioactive peptides in fermented milk, including the bioactive ACE-I peptide.

The value of IER ranged from 5.68±0.62 to 16.33±1.72. The value of IER represents the effectiveness of peptide in inhibiting ACE activity. The value of IER is obtained by dividing the percentage of ACE-I activity by peptide content. High IER values indicate inhibitory efficiency against ACE. The highest IER value was obtained in milk fermented by *L. lactis* ssp. *lactis* BD17, but the difference was not significant (\>0.05) than milk fermented by *L. kefiri* YK4, *L. kefiri* JK17, and *L. plantarum* 1 W22408.

Fermented milk of *L. kefiri* YK4 had a lower IC~50~ value than fermented milk of *L. kefiri* JK 17. IC~50~ values obtained from both samples were still lower with that of reported by Qian *et al*. \[[@ref52]\] who used *L. delbrueckii* ssp. *bulgaricus* LB to ferment milk and resulted in the IC~50~ values of 67.71±7.62 mg/mL; Moslehishad *et al*. \[[@ref53]\] used *L. rhamnosus* PTCC 1637 with the IC~50~ value of 3.947±0.029 mg/mL; and Chen *et al*. \[[@ref54]\] in koumiss with IC~50~ of 52.47±2.87 mg/mL.

After partial purification using membrane filtration 3 kDa, the activity ACE-I of \<3 kDa fraction of *L. kefiri* YK4 was not significantly different from the whole extract, but significantly higher than the fraction of \>3 kDa. This finding indicated that the active peptides were mainly at \<3 kDa. The 3 kDa filtration is a widely used and effective way of obtaining and identifying ACE-I peptides, as ACE-I activity is produced mainly by peptides with \<3 kDa fractions \[[@ref26],[@ref42],[@ref55]\]. However, the whole supernatant of *L. kefiri* JK17 was significantly higher than its \<3 kDa fraction. This result is similar to the results of Chen *et al*. \[[@ref54]\] that koumiss fermented milk supernatant had a higher ACE-I activity compared to the \<3 kDa fraction.

The dominant proteins hydrolyzed by *L. kefiri* YK4 were β-casein and αs1-casein by *L. kefiri* JK 17 ([Table-5](#T5){ref-type="table"}). This finding explains the difference between the two strains in the proteolytic system. The hydrolysis of non-casein proteins (ά-lactalbumin, β-lactoglobulin, and serum amyloid A) also showed that both isolates had high proteolytic activity. Some LAB such as *Bifidobacterium* and others are known to produce peptides only from casein. Peptides that have ACE-I activity ([Table-6](#T6){ref-type="table"}) are generally originated from β-casein, αS1-casein, and ĸ-casein. *L. kefiri* YK4 hydrolyzed 362 peptides from ĸ-casein in fermented milk. ĸ-casein is glycomacropeptides consisting of glycine chains reported in several studies that are heavily hydrolysis-resistant \[[@ref56]\]. This resistance was related to the presence of hydrophilic amino acids and negative charges.

ACE-I activity was related to the structure of the peptide \[[@ref57]\]. A total of 21 ACE-I peptides obtained from the present research ([Table-6](#T6){ref-type="table"}) are peptides that have amino acid proline residues in the C-terminal chain. Residues of tripeptide amino acids, such as proline in the C-terminal chain, play a significant part in binding to the active side ACE \[[@ref57]\]. In addition to proline, phenylalanine amino acid residue was also identified in 19 ACE-I peptides in the C-terminal chain. Residues of lysine amino acid were also found in five peptides of ACE-I ([Table-6](#T6){ref-type="table"}).

In this study ([Table-6](#T6){ref-type="table"}), the peptide ACE-I has a residue of 6-16 amino acids with an MW of \<2 kDa. Some researchers have previously reported that ACE-I bioactive peptides are generally short peptides with residues of 2-6 amino acids \[[@ref58],[@ref59]\] or longer peptides with 9-16 amino acids \[[@ref4],[@ref60]\] even up to 20 amino acid residues \[[@ref30],[@ref61]\].

Conclusion {#sec1-5}
==========

The ten LAB isolates produced ACE-I activity in fermented milk. The activity of ACE-I above 50% was obtained in milk fermented by *L. delbrueckii* BD7, *L. lactis* ssp. *lactis* BD17, and *L. kefiri* YK4 and JK17. The highest activity of ACE-I was found in milk fermented by *L. kefiri* YK4 (IC~50~ of 0.261 mg/mL) and *L. kefiri* JK17 (IC~50~ of 0.308 mg/mL). Results of peptide identification in the \<3 kDa fraction showed that *L. kefiri* YK4 and *L. kefiri* JK17 could release peptides. The peptides produced were 95% derived from casein. A total of 30 peptides obtained in the present study have been recognized based on the literature searches as ACE-I peptides. *L. kefiri* YK4 and JK17 have the potential to be used as starter cultures in the production of bioactive ACE-I peptides. The two isolates could be used to support the strategies for promoting fermented milk products as a source of bioactive peptides that will benefit to health.
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